Compare Bristol-Myers Squibb Co (BMY) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Vanguard Growth Index Fund ETF — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Vanguard Growth Index Fund ETF trades at $87.21. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Vanguard Growth Index Fund ETF pays none, and Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Bristol-Myers Squibb Co nearer its low. Which is the better fit depends on your goals.
| BMY | VUG | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Sector/Thematic |
52-Week High | $62.37 | $90.29 |
52-Week Low | $42.60 | $70.00 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
VUG trades at $86.15, down 1.43% on the day, with a neutral technical signal and bullish moving averages. Recent news highlights its low 0.03% expense ratio and 411% total return over the past decade. The ETF is heavily concentrated in technology stocks (70% of assets) and executed a 1:6 stock split in April 2026.
Outlook remains positive for long-term growth investors given strong historical performance and cost efficiency, though high tech exposure and market volatility present risks. The fund's ability to adapt to economic growth trends supports its appeal, but investors should weigh concentration risk against diversification benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
